Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector
ZacksBiogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA for Leqembi subcutaneous autoinjector as a weekly maintenance dosing regimen for early Alzheimer’s disease.